4 terminated, 2 completed, 1 recruiting. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 4, Completed 2, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Epilepsy, Absence: new trials by email Literature Review of Epilepsy, Absence trials Research Report on Epilepsy, Absence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Completed | NeuroPro Therapeutics, Inc. | 14 | 2025-03-11 | 2026-09-28 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| Flunarizine for Treatment Resistant Absence Epilepsy Flunarizine Hydrochloride - Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 2 | Terminated | University of British Columbia | 9 | 2019-09-20 | 2023-12-01 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 11 | 2018-02-20 | 2023-06-18 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Cannabidiol Oral Solution - Childhood Absence Epilepsy | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 20 | 2017-12-29 | 2023-07-21 |
| A Pilot Study of Topiramate in Childhood Absence Epilepsy topiramate - Epilepsy, Absence | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 12 | 2005-03-01 | 2011-06-10 |
Epilepsy (2) · Epilepsy, Generalized (2) · Myoclonic Epilepsy, Juvenile (2) · Seizures (2) · Drug Resistant Epilepsy (1) · Epilepsies, Myoclonic (1) · Epilepsy, Idiopathic Generalized (1) · Lennox Gastaut Syndrome (1)
Brain Diseases (7) · Central Nervous System Diseases (7) · Epileptic Syndromes (7) · Nervous System Diseases (7) · Epilepsy (5) · Epilepsy, Generalized (5) · Epilepsies, Myoclonic (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1)
Cannabidiol (2) · Flunarizine (1) · Topiramate (1)
Radius Pharmaceuticals, Inc. (2) · Biohaven Therapeutics Ltd. (1) · Bright Minds Biosciences Pty Ltd (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · NeuroPro Therapeutics, Inc. (1) · University of British Columbia (1)
United States (4) · Australia (2) · Austria (1) · Belgium (1) · Canada (1) · Croatia (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Ahmed Elkashef, MD (2) · Terence O'Brien, MD (1)
2023 (1)